rs58194899 — EIPR1

Intronic variant in EIPR1 (endosomal trafficking protein) associated with pain sensitivity via neuropeptide vesicle regulation

See your personal result for EIPR1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

EIPR1 — The Vesicle Trafficker That Sets Your Pain Thermostat

Pain is not simply a signal your nerves generate — it is a sensation your brain calibrates continuously, amplifying or dampening incoming nociceptive input based on the availability of pain-modulating neuropeptides. The EIPR1 gene11 EIPR1 gene
EARP complex and GARP complex interacting protein 1; also known by its original name TSSC1 (tumor-suppressing subtransferable candidate 1); located on chromosome 2p25.3 encodes a WD40-domain protein that sits at an unexpected point of control in this system: the sorting of neuropeptides into the dense-core vesicles that neurons use for regulated, stimulus-triggered release.

The Mechanism

EIPR1 acts as a molecular bridge between two endosomal trafficking complexes — EARP (endosome-associated recycling protein)22 EARP (endosome-associated recycling protein)
Retrieves membrane proteins from endosomes back to the plasma membrane and GARP (Golgi-associated retrograde protein), which returns cargo from endosomes to the trans-Golgi network. Together these complexes manage the endosomal sorting compartment, a staging area through which neuropeptide precursors pass on their way into mature dense-core vesicles (DCVs).

Dense-core vesicles33 Dense-core vesicles
Large secretory organelles distinct from conventional synaptic vesicles; they package and release neuropeptides, biogenic amines, and peptide hormones including substance P, CGRP, enkephalins, and brain-derived neurotrophic factor are the primary vehicles for neuropeptide secretion throughout the nervous system. When EIPR1 function is impaired, cargo fails to sort correctly into maturing DCVs — it accumulates in the perinuclear region rather than being packaged and shipped to axonal terminals. Loss of EIPR1 in insulin-secreting cells reduces regulated secretion44 Loss of EIPR1 in insulin-secreting cells reduces regulated secretion
Topalidou et al. 2020 and disrupts EARP localization on endosomal membranes.

In the brain, EIPR1 is expressed broadly, with highest levels in the basal ganglia, cerebral cortex, amygdala, and hypothalamus — regions central to both pain processing and descending pain modulation. The intronic rs58194899 variant likely modulates EIPR1 expression or splicing efficiency in a tissue-specific manner rather than altering the protein sequence directly. The A allele, which reduces pain sensitivity, may increase EIPR1 activity or expression in relevant neural circuits, improving neuropeptide packaging and thereby enhancing endogenous pain suppression.

The Evidence

Fontanillas et al. 202255 Fontanillas et al. 2022
23andMe GWAS; 25,321 participants scored on the Pain Sensitivity Questionnaire; cold pressor test arm (n=6,853) did not replicate this signal performed the largest genetic analysis of self-reported pain sensitivity to date. The rs58194899 A allele reached genome-wide significance (OR = 0.950, 95% CI 0.933–0.967, p = 1.9 × 10⁻⁸, MAF = 0.47) for lower PSQ scores, meaning each copy of the A allele is associated with approximately 5% lower odds of rating yourself as highly pain sensitive. The haplotype block spans 54 variants entirely within EIPR1's boundaries, implicating the gene specifically.

Importantly, the signal was not replicated in the cold pressor test (CPT) arm (p = 0.58), suggesting this variant influences subjective pain perception and central sensitization rather than peripheral nociceptive thresholds measured by acute cold pain tolerance.

Pathway enrichment analysis in the same study showed that PSQ-associated genes are overrepresented in neuronal development and glutamatergic synapse signaling pathways — consistent with a mechanism involving neuropeptide modulation of synaptic plasticity and central sensitization.

Recent clinical genetics work Ghosh et al. 202566 Ghosh et al. 2025
Eight individuals from six families with homozygous pathogenic EIPR1 variants; global developmental delays, corpus callosum underdevelopment, cerebellar atrophy confirms that severe EIPR1 loss of function produces a neurodevelopmental disorder with hallmark endolysosomal and dense-core vesicle defects — providing strong biological plausibility that common regulatory variation at this locus modifies neural function along a continuum.

The evidence level is rated emerging: the GWAS association is genome-wide significant and biologically coherent, but there is currently one discovery study without independent replication, and the functional mechanism (how exactly the intronic variant modulates EIPR1 in pain-relevant circuits) has not been characterized.

Practical Actions

This variant does not predict response to a specific drug class the way CYP2D6 or OPRM1 variants do. Instead, it shifts the baseline at which you perceive and report pain — a contextual factor that informs analgesic strategy and pain assessment.

For the GG genotype (higher pain sensitivity): standard pain scales may underestimate the need for analgesic coverage, particularly for perioperative and chronic pain. A proactive, multimodal approach — combining pharmacological and non-pharmacological pain management — is more likely to achieve adequate control than relying on reactive dose escalation.

For the AA genotype (lower pain sensitivity): standard doses of analgesics may provide sufficient effect, but there is also a risk of under-recognition of pain (your own and by providers) in conditions where pain is a key diagnostic signal.

Interactions

The pain sensitivity pathway involves multiple genetic modulators. OPRM1 rs179997177 OPRM1 rs1799971
Mu-opioid receptor A118G variant — G allele reduces receptor expression and opioid efficacy independently affects opioid analgesic response. Individuals carrying both high-sensitivity EIPR1 GG and OPRM1 G alleles face a double challenge: heightened pain experience combined with reduced opioid effectiveness. The COMT rs468088 COMT rs4680
Catechol-O-methyltransferase Val158Met — Met/Met associated with lower dopamine catabolism and higher pain sensitivity is another convergent pain sensitivity modifier worth considering when interpreting EIPR1 GG results. These interactions are not yet characterized in combined analyses and cannot support specific compound action recommendations, but awareness of co-occurring risk genotypes is clinically useful.

Drug Interactions

opioid analgesics (class) dose_adjustment literature
NSAIDs dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

AA Reduced Pain Sensitivity Beneficial

Protective EIPR1 variant associated with lower subjective pain sensitivity

The protective effect is specifically for subjective pain perception as measured by questionnaire. It was not replicated in the cold pressor test (an objective nociceptive threshold measure), suggesting the A allele modulates central pain processing and how pain is interpreted and reported rather than peripheral sensory thresholds. Clinically, this may mean you tend to rate pain lower on numeric scales than average, which has implications for pain management: there is a risk that your reported pain scores lead to under-treatment, and that serious pathological pain may be underweighted diagnostically. Proactively communicating about pain to healthcare providers, rather than relying on scale numbers, is appropriate.

AG Intermediate Pain Sensitivity Intermediate

One protective A allele — slightly below-average pain sensitivity

Heterozygotes for rs58194899 fall between AA and GG in the additive model established by the GWAS. The per-allele OR of 0.950 translates to approximately 5% reduced odds of high pain sensitivity per A allele — meaning AG individuals have ~5% lower odds than GG individuals. This is a small but consistent effect. From a clinical perspective, your pain reporting on standard scales should be interpreted as reasonably representative of your tissue state, though there is a mild tendency toward under-reporting compared to GG carriers.

GG Elevated Pain Sensitivity High Risk

Higher genetic pain sensitivity — proactive pain management strategy recommended

The GG genotype reflects reduced expression or function of EIPR1 in pain-relevant brain circuits (the precise mechanism is not yet fully characterized for this intronic variant). EIPR1 coordinates the endosomal trafficking machinery that sorts neuropeptides — including endogenous opioids, substance P, and CGRP — into dense-core vesicles for regulated release. Reduced EIPR1 activity means less efficient neuropeptide packaging and potentially impaired endogenous pain suppression.

The clinical implication for pain management is that standard analgesic dosing protocols may be insufficient for GG individuals with significant pain conditions, since the baseline level of subjective pain experience is higher. This is consistent with observations across other pain sensitivity variants — higher baseline sensitivity predicts both greater perioperative analgesic requirements and higher rates of chronic pain progression after acute events.

The GWAS signal did not replicate in the cold pressor test, suggesting this variant primarily affects central sensitization and the subjective amplification of pain rather than peripheral nociceptive thresholds. This is the clinically relevant distinction: the GG genotype is most likely to matter in chronic pain, postoperative pain, and conditions involving central sensitization (fibromyalgia, migraine, IBS with pain).